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Abstract
Background: Randomized controlled trials (RCTs) are the ‘gold standard’ in the generation of drug efficacy and
safety evidence. However, enrolment criteria, timelines and atypical comparators of RCTs limit their relevance to
standard clinical practice.
Discussion: Real-world data (RWD) provide longitudinal information on the comparative effectiveness and
tolerability of drugs, as well as their impact on resource use, medical costs, and pharmacoeconomic and
patient-reported outcomes. This is particularly important in multiple sclerosis (MS), where economic treatment
benefits of long-term disability reduction are a cornerstone of payer drug approvals – these are typically not
examined in the RCT itself but modelled using real-world datasets. Importantly, surrogate markers used in RCTs to
predict the prevention of long-term disability progression can only truly be assessed through RWD methodologies.
Summary: We discuss the differences between RCTs and RWD studies, describe how RWD complements the
evidence base from RCTs in MS, summarize the different methods of RWD collection, and explain the importance
of structuring data analysis to avoid bias. Guidance on performing and identifying high-quality real-world evidence
studies is also provided.
Keywords: Multiple sclerosis, Real-world evidence, Real-world data, Randomised controlled trials, Registries,
Pharmacoeconomics
An introduction to real-world evidence (RWE) in
multiple sclerosis (MS)
In general, randomised controlled trials (RCTs) and RWE
studies are important for improving our understanding of
disease outcomes and treatment effects, with the two
methodologies being increasingly viewed as complemen-
tary by clinicians, the pharmaceutical industry, drug regu-
latory and reimbursement agencies, and patients [1]. The
prominence and value of RWE studies (Box 1) have made
them mandatory in many settings; however, inherent vari-
ability in patient care means that their analysis requires
particular care. Figure 1 summarises the key differences
between RCTs and RWE studies.
In MS, there is a current and growing emphasis on
obtaining data beyond phase 3 RCTs. In 2014, the
number of published RWE studies in MS exceeded that
of published phase 2 and 3 studies by more than two-
fold (Fig. 2). This has been driven by increasing demand
from payers and healthcare decision-makers for post-
approval evidence to inform reviews of pricing, reim-
bursement, licences for new therapies, and formulation
and indication changes [2]. Post-approval RWE studies
are important for providing information on compliance
with current treatment guidelines, identifying subopti-
mal therapies, defining treatment responder subgroups,
optimizing treatment sequencing, and monitoring rare
serious adverse events. This information can support li-
cence extensions and treatment sequencing [3].
RWE studies can also provide valuable insights prior
to product development. Pre-launch RWE studies, for
example, are useful for mapping out the natural and
drug-modified history of disease, current practice pat-
terns and service structures [3]. In MS, this can go some
way to meeting the need for information on disease
characteristics, treatment behaviours, and healthcare
availability for ‘real’ patients with the disease. Closer to
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product launch, RWE can provide further insights into
early clinical experience, safety, resource use, patient tol-
erability, and identification of untreated patients [3].
MS is a lifelong disease that can span more than
40 years. The short duration of RCTs provides limited
information on MS disease course and long-term treat-
ment effects. RCTs alone may be acceptable in acute
neurological diseases like meningitis and stroke, where
discrete endpoints, such as survival or post-acute fixed
disability, can be swiftly measured. Conversely, for MS,
the potential effects of a disease-modifying therapy (DMT)
on disease progression can only be obtained by collecting
information on patients treated in routine clinical practice
over many years. The endpoints commonly used in phase 2
and 3 MS studies, such as inflammatory lesions and relapse
rates, are important surrogate markers for predicting the
anticipated long-term prevention of disability, and these
can only be validated via RWE methodologies.
Collection of high-quality real-world data (RWD)
in MS
Regardless of disease area, collection of high-quality data-
sets in clinical practice requires agreement on a common
minimum dataset and the use of special documentation
software (or modifications to existing electronic medical
records) to collect demographic and disease-specific in-
formation. These standards are important to offset the
perception that the quality of RWD is inferior to that
gathered in sophisticated, modern-day RCTs. Electronic
medical record-based data collection is usually event
based, with visits and other data being recorded as they
occur, whereas RCTs use a schedule design where the
timing and data collection at each visit are explicitly
specified. In MS, event-based reporting currently pre-
dominates (e.g. the Swedish MS registry (SMSreg), the
European Database for Multiple Sclerosis system, and
Fig. 1 The key differences between randomized controlled trials and
real-world evidence studies [1, 3, 4]
Box 1. About real-world evidence (RWE) studies [1, 5]
Randomised controlled trials (RCTs) are the ‘gold standard’ in
the generation of efficacy and safety evidence of a product in
restricted trial settings.
Advantages
1. Can mimic RCTs in the real world to allow assessment of a
drug in the clinical setting
2. Complement the evidence base from RCTs by assessing a
diverse range of outcome measures to provide information
that may not be captured by other means, including:
• comparative effectiveness data between multiple therapies
• information on long-term disability outcomes





1. They cannot address the potential benefits and risks of a
product in the real world [1, 5] because enrolment is
restricted by disease-activity criteria, and subjects with
comorbid conditions are typically excluded
2. Active comparator arms may not reflect the usual standard of
care and selected endpoints can be artificial or chosen to
maximize statistical power, thereby limiting the real-world
relevance of study conclusions
3. There are significant ethical concerns about conducting
placebo-controlled trials in countries where disease-modifying
therapies are approved and reimbursed [2]; these pivotal trials
are therefore conducted in countries without these approvals,
and thus in populations different to potential target markets
4. There are many potential biases in real-world treatment
comparisons and variations in data quality caused by
acquisition in busy clinics
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the iMED software used for data entry into the MS
dataBase (MSBase)), although this is governed by speci-
fied minimum dataset descriptions. In contrast, the
Multiple Sclerosis Documentation System 3D software
used in multiple long-term follow-up studies imposes a
defined visit schedule and is used predominantly in
Germany, where it combines a ‘trial-like’ data docu-
mentation system with patient management [4]. Table 1
summarizes common sources of RWD [5] and gives ex-
amples of their use in RWE studies in MS [6–20].
Performing and identifying high-quality RWE
studies in MS
In MS, RWD is increasingly used for comparison studies
to examine therapy choice and sequencing decisions.
Outcomes are similar to those in RCTs and include re-
lapse and disability progression rates, adverse events and
therapy discontinuation events. Identification and mitiga-
tion of biases and careful consideration of study power are
key factors for designing appropriate RWE studies. Indeed,
various biases exist and require careful consideration in
selecting appropriate comparators, patient populations,
data sources, outcomes and statistical analyses [21].
Selected analytical techniques (e.g. regression and
stratification) can reduce the bias introduced by non-
randomized study designs. Regression can improve the
accuracy of an estimated treatment effect on a particular
outcome measure by adjusting the association between
treatment and outcome to account for other variables that
could affect said outcome. In MS, these variables include
baseline Expanded Disability Status Scale (EDSS) score,
prior relapse rate and disease duration. The type of regres-
sion model used largely depends on the outcome being
measured [22]. Logistic regression is typically used for bin-
ary outcome measures (e.g. event occurred: yes/no), while
proportional hazard estimates are used for continuous
outcome measures (e.g. time to first relapse) [22]. Import-
antly, regression analysis uses all available data from the
full patient cohort, enabling good statistical power, al-
though it assumes that similar effects of an intervention
occur across all subgroups and requires extrapolation
when calculating estimates [22].
Stratification, whereby patient cohorts are divided into
subgroups with similar variables, enables comparison of
outcomes among patients with similar characteristics [22].
However, the potential for imbalance in other baseline co-
variates [22] requires the careful generation of statistically
robust results, and sample sizes are necessarily smaller
than for regression, reducing statistical power [22].
In many circumstances, propensity scoring has proven
effective at reducing bias and is being used increasingly
in longitudinal MS observational studies. In studies
comparing the effect of two treatments, propensity scor-
ing involves classification of the relationship between
treatment assignment and baseline characteristics. Fac-
tors found to be different between treatment groups
and associated with treatment choice are weighted to
calculate the probability of any subject in the cohort
being assigned a particular treatment – this is termed


























Fig. 2 Number of multiple sclerosis (MS) articles of different study types published in 2014. Numbers of each type of study were found by searching
the PubMed database for articles published between January 1, 2014, and December 31, 2014, using the following search terms: for phase 2 clinical
trials: (‘multiple sclerosis’ OR ‘MS’) AND (‘Phase II clinical trials’ OR ‘Phase 2 clinical trials’); for phase 3 clinical trials: (‘multiple sclerosis’ OR ‘MS’) AND
(‘Phase III clinical trials’ OR ‘Phase 3 clinical trials’); For real-world evidence studies: (‘multiple sclerosis’ OR ‘MS’) AND (‘real world’ OR ‘comparative
effectiveness’ OR ‘registry’); for case studies: (‘multiple sclerosis’ OR ‘MS’) AND (‘case study’)
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propensity score for comparison across treatment groups
[23]. In effect, ‘unmatchable’ subjects, in whom a particular
set of baseline characteristics leads to non-overlapping
treatment assignment within a population, are removed
from the outcome analysis and only ‘matchable’ subgroup
outcomes are reported. Propensity scores can be used to
aid stratification or regression through posterior adjust-
ment of results [23]. When there are fewer than eight
events per confounder, propensity scoring has been found
to be a more robust method of eliminating bias than
regression [24].
The introduction of bias through lack of randomization
and blinding, as well as other methodological limitations
of RWE studies, has raised questions about the validity of
the evidence produced [25]. With this in mind, efforts
have been made to promote good research practice and to
advise researchers designing RWE studies to maximize the
usefulness of the results obtained [21]. For cohort studies
in general, checklists have been produced for both RCTs
(CONSORT) [26] and for more general cohort studies
(STROBE) [27]. Specifically for RWE studies, Dreyer et al.
[28] recently compiled the Good Research for Compara-
tive Effectiveness checklist to allow identification of RWE
studies sufficiently high in quality for use in decision-
making. Box 2 summarizes this checklist and the 10 ‘golden
rules’ for identifying high-quality RWE studies, all of which
are relevant to study design in MS.
How has RWE helped in understanding the
disease course and patient management in MS?
RWE generated from quality registries and other databases
has greatly contributed to our understanding of MS disease
course and risk factors. RWE studies have reported a de-
creased life expectancy for patients with MS compared with
the general population [29], and have shown how factors
such as increased age at disease onset and the primary pro-
gressive subtype of MS are associated with faster disability
progression [30, 31]. They have also shown that, despite
high variability in individual patients following conversion
to secondary progressive MS and in patients with primary
progressive MS, the mean or median progression rates be-
tween these disease subtypes are similar [31]. Other RWE
studies have indicated a lower familial risk for developing
MS than previously predicted [19], as well as an influence
of race on outcomes [32].
RWE has also helped to guide patient management
and treatment decisions in MS by answering questions
related to treatment effects in clinical practice, which
RCTs are unable to address. These effects are discussed
in turn in the following sections.
Table 1 Methodologies for collecting real-world data [4] and examples of their application to multiple sclerosis (MS) studies
Source Explanation Advantages Limitations Examples in MS
RCTs extensions • Supplement trial data • Extend RCT into real world • Short study duration
• Limited patient population
• No information on rare events
• ENDORSE: EQ-5D and SF-36 in









• Incomparable patient groupings
• Discontinuous visit schedule
• Varying practice patterns
• Inter-regional extrapolation not
always appropriate
• Lyons MS database: disability
progression [11]
• SMSreg: epidemiology and
treatment outcomes [16, 19]
• MSBase: treatment outcomes






• Robust dataset powered
to answer specific questions
• Hawthorne effect (patients
behave differently because they
know they are being observed)
• PANGAEA, TOP: fingolimod and
natalizumab clinical trial [9, 20]
PASSs • Voluntary or imposed
by regulatory
authorities for approval
• Ongoing monitoring of
the benefit–risk profile
• No obligation for regulatory
submission of protocols and
study reports for voluntary PASSs
• PANGAEA: German voluntary
PASS [20]
Administrative data • Data required for
reimbursement
• Quick, low-cost analyses
• Large patient populations
provide information on
rare events
• Privacy concerns limit access to
data
• Incomplete or inaccurate data
• Costs and charges are not
differentiated
• Pharmetrics Plus™ and Medco
databases: relapses, treatment
compliance, resource use and
inpatient stays [6–8]




• Relies on participant recollection
• NARCOMS survey: symptoms,
comorbidities and health-related
quality of life [18]
EMRs • Real-time data
collection
• Low cost
• Detailed information over
long periods
• High-end statistical analysis tools
required
• EMRs: diagnosis, disease
progression, symptoms and
treatment [12]
DMF, Dimethyl fumarate; EMR, Electronic medical record; ENDORSE, BG00012 monotherapy safety and efficacy extension study in MS; EQ-5D, European Quality of
Life-5 dimensions questionnaire; MSBase, Multiple Sclerosis dataBase; NARCOMS, North American Research Committee on Multiple Sclerosis; PANGAEA,
Post-Authorization Noninterventional German sAfety of GilEnyA in RRMS patients; PASS, Post-authorization safety study; RCT, Randomized controlled trial;
SF-36, 36-Item Short Form; SMSreg, Swedish MS registry; TOP, TYSABRI Observational Program
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Comparative effectiveness of DMTs in clinical practice
In the RWE setting, comparative effectiveness of DMTs
can be determined from registry data. In MS, web-based
registries, such as MSBase and SMSreg, can provide this
type of information at global and regional levels [16, 33].
For instance, data from SMSreg have shown that fingoli-
mod treatment initiation is associated with stable EDSS
scores and improvement in relapse rates, disease severity,
cognition, and quality of life after 12 months [16]. MSBase
data analyses have also demonstrated the positive effect of
DMT treatment on first confirmed disability progression
[34] and have been used extensively for comparative ef-
fectiveness studies to show that, in patients who relapse
on ‘platform’ injectable DMTs, switching to fingolimod
or natalizumab, rather than between injectable DMTs,
can lead to improvements in time to first relapse, relapse
rate, and disability progression and regression events
[17, 35]. Interestingly, after relapse on platform therapy,
Box 2. The ten golden rules for identifying high-quality real-world evidence (RWE) studies [28]
Rules for identifying high-quality RWE studies
1. Treatment details and primary outcomes should be adequately recorded
• Sufficient detail should be recorded so that information on treatment, including dose, regimen and mode of administration, can be
determined
• Enough meaningful and robust information to allow primary outcomes of the study to be established
2. Primary outcomes should be measured objectively
• Objective primary outcome measures help to reduce bias between datasets
• Objective primary outcome measures for multiple sclerosis (MS) would include the number and volume of T2 lesions and disability
progression as measured by the Expanded Disability Status Scale (EDSS)
3. Primary outcomes should be valid [28]
• The primary outcomes for the study should be appropriate for the research question to be answered (e.g. EDSS progression and
relapse rate in MS, and claims data for resource use)
4. Primary outcomes should be identified and measured equally in treatment and comparison groups
• Data, tools and methods used for evaluating primary outcomes should be identified and measured in the same way in both the
treatment and the comparison groups• Comparator arms should be clinically relevant [1]
5. Confounders of treatment effect should be recorded
• Any variables that could potentially impact the primary outcome of the study should be recorded (e.g. in MS, age of onset of
disease, number of relapses in the year prior to start of the study, EDSS score at entry into study, previous treatment with
disease-modifying therapies, and number of lesions at baseline)
6. The study population should be restricted to new users of the treatment being assessed
• Include only treatment-naïve patients to enable the frequency of early treatment effects to be determined and to limit bias
associated with delayed treatment or loss of effectiveness
• If treatment naivety cannot be achieved, then washout should be considered
7. Data should be collected for the same time period for treatment and comparison groups
• Data from patients in treatment and comparator groups should be from within the same time period to ensure that the same
standard of care is applied to both groups and that time-dependent effects are minimised
• Historical data may be used in some cases (e.g. when comparing with older treatments that are no longer widely used)
8. Confounders of treatment effect should be taken into account in the study design and analysis
• Studies should either restrict patient inclusion or employ analytical methods such as propensity scoring, stratification and regression
to control for confounding factors
• Methods used for reducing bias should be properly reported; however, it is still important to be aware of the limitations of the
statistical techniques used to reduce bias as they can lead to an inaccurate estimation of the effect of a treatment [1]
9. The study design should take into account ‘immortal time bias’
• Study design should ensure that any events that occur before treatment exposure (in ‘immortal time’) are not included in the
analysis, as this can exaggerate drug benefits
10. Key assumptions on which primary outcomes are based should be analyzed
• Assumptions should be analysed to verify their validity and reduce bias
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a comparison of switch to fingolimod versus natalizumab
indicated that switching to natalizumab from baseline
therapies reduced relapse rates and increased sustained
disability regression events more than switching to fingoli-
mod, but that there was no difference in the rate of con-
firmed progression events between these treatments [14].
MSBase registry data also confirmed that relapse rates in
patients switching to fingolimod from natalizumab were
comparable to those switching from other therapies, and
that an ideal treatment gap between these therapies was
less than 8 weeks to reduce risk of early relapse [13] – a
finding subsequently confirmed in an RCT [36]. MSBase
data have also demonstrated variations between different
baseline therapies, with patients treated with glatiramer
acetate or subcutaneous interferon β-1α experiencing
fewer relapses than those taking other baseline therapies
[15]. Importantly, MSBase analyses (using propensity
score matching) have generally replicated RCT results
where known and align well with clinician experience,
suggesting that biases are properly addressed using this
dataset and statistical methodology.
Safety and tolerability of a DMT in clinical practice
Registries are also a good source of information on safety
and tolerability of a product in a real-world setting. The
Immunomodulation and Multiple Sclerosis Epidemiology
studies used SMSreg data to show that, although fingoli-
mod and natalizumab are both well tolerated, fingolimod
tolerability is reduced compared with that of natalizumab,
especially in patients switching from natalizumab [37].
The Post-Authorization Noninterventional German sAfety
of GilEnyA in RRMS patients (PANGAEA) study is a
prospective, observational, registry-based study designed
to collect data on effectiveness and adverse events in
fingolimod-treated patients in standard clinical practice
[20]. Prospective observational studies performed without
registry data also provide an insight into the safety and tol-
erability of MS treatments in the real world, albeit on a
smaller scale. The Safety, Tolerability and Adherence with
Rebif© study and Tysabri Observational Program interim
analysis, for example, demonstrated that the safety profiles
of subcutaneous interferon β-1α and natalizumab in
relapsing-remitting MS patients in clinical practice are
comparable with those in RCTs [9, 38].
Impact of a DMT on resource use and medical costs
Claims databases provide valuable data on the impact of
DMTs on resource use and medical costs, such as use of
other medications and hospital stays. These pharmacoe-
conomic considerations are important influencing fac-
tors in formulary decisions. IMS PharMetrics Plus™ is a
medical and pharmacy claims database containing the
records of over 100,000 patients with MS across the
USA [7, 8]. This dataset has been used to distinguish the
effects of different DMTs on outcome measures such as
adherence, persistence, inpatient stays and corticosteroid
use for relapses [7, 8].
Impact of a DMT on pharmacoeconomic outcomes
Pharmacoeconomic studies provide an insight into the
cost-effectiveness of a DMT, including the direct effect of
medication costs and indirect costs from health-related
work absences or caregiver time. The PANGAEA and Pro-
spEctive phArmacoeconomic cohoRt evaLuation (PEARL)
registry studies of fingolimod- and injectable DMT-treated
patients collect data on sick leave, hospitalization and phys-
ician consultations, and show that fingolimod treatment re-
sults in better pharmacoeconomic outcomes compared
with baseline therapies [39]. Similar results have been ob-
served with natalizumab treatment in patients in the USA
through analysis of administrative claims databases [40].
Impact of a DMT on patient-reported outcomes (PROs)
Patient-generated data can be used to assess the perceived
clinical benefits of a therapy and is useful for examining
other aspects of patient experiences with DMTs. Some
RCTs, such as the Evaluate Patient Outcomes study [41],
which assessed treatment satisfaction in patients treated
with fingolimod or injectable DMTs, collect patient-gener-
ated data. Some observational RWE studies also assess
PROs. PANGAEA and PEARL were designed to cap-
ture patient experience on effectiveness, tolerability
[20] and treatment satisfaction, as well as on ease and
convenience of taking their DMT as instructed [20, 42].
Additional PROs on quality of life, physical disability,
cognition and fatigue can be obtained through health
surveys [43].
Evolving RWD collection in MS
Many countries across the world now collect MS RWD
in registries and other databases [30, 44] (Table 2), and
sharing of this information is critical to increase statistical
power and to enable inter-regional knowledge transfer. Col-
laborations between MS registries, such as the European
Register for Multiple Sclerosis, which includes data from 13
registries in Europe [45], further highlight the importance
of information-sharing and learning on an international
level by providing expanded datasets that allow cross-
border analysis, interpretation and dissemination of results.
Another collaborative example is the BigMS collaboration
between MSBase and registries in France, Italy, Sweden
and Denmark, which contains quality longitudinal datasets
for over 130,000 patients with MS, with the first joint ana-
lyses planned for 2016. However, while the sharing of regis-
try data sounds like an obvious positive step, in some cases
this is not possible because it may breach the original
patient consent. In these cases, efforts should be made to
either re-contact the patients or to strip out all patient
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identifiers before the data are shared. Certainly, with the
modem age of big data and the need to combine datasets
to improve statistical power, consent to share data ought to
be included in the consent forms for any new programmes.
MS RWD can be collected within registries that
contain information on other disorders that can be used
to inform neurologists and improve patient management
across a range of neurologic diseases. The Swedish
Neuro Registries includes MS RWD from SMSreg as
well as other disease-specific data, including Parkinson’s
disease, epilepsy and myasthenia gravis. However, disease
specificity and usability of registry data is fundamentally
assured by the registry participant’s agreement to collect
a uniformly defined ‘minimum dataset’ at a relatively set
frequency. This is a major limitation of MS registries,
and if data are to become more reliable and powerful,
then standards for data input are needed and these need
to be audited with validated quality control checks.
Although registries currently collect information on a
variety of different clinical, pharmacoeconomic and safety
outcome measures, the quality of magnetic resonance im-
aging (MRI) data in MS registries is currently limited. The
descriptive, semi-quantitative MRI T2 lesion measures
that are often recorded (e.g. Barkhof–Tintoré criteria) cap-
ture the severity of cerebral and spinal cord MRI abnor-
malities in MS relatively poorly, although they do provide
a broad characterisation of lesion load and location.
The argument for inclusion of better, standardised MRI
data in registries, and indeed their acquisition in clinical
practice, is strong. MRI provides evidence of disease activity
in MS [46] and new T2 hyperintense and T1 hypointense
lesion development, particularly whilst on treatment, corre-
lates with long-term disability progression [47, 48]. The in-
creased rate of brain volume (BV) loss in patients with MS
compared with healthy controls [49], indicating myelin,
axonal and neuronal loss [50], is associated with cognitive
impairment and disability in MS [51–53]. As BV loss is dif-
ferentially affected by different MS therapies, standardized
measures of BV change in clinical practice captured in real-
world registries could provide information on the relative
efficacy of MS therapies [54], with such information war-
ranting inclusion in prognostic models. Inclusion of quanti-
tative baseline MRI parameters would also improve patient
matching to compare different treatment switch decisions
in long-term RWE studies. We believe that a technological
solution is imminent. Indeed, third party providers per-
forming online automated MRI analytics (e.g. IcoMetrix,
NeuroQuant) are emerging and have achieved medical
device registration for use in clinical practice. The MRI
manufacturers themselves are also developing automated
lesion and BV algorithms that will likely be incorporated in
standard MRI analytical packages within the next 2 years.
Importantly, RWE collection systems are becoming
increasingly flexible, with the ability to exchange data
with different sources (e.g. physician-, MRI- and patient-
generated data) [55]. Additionally, key providers of RWD
collection systems understand the need for creating added
value for contributing clinicians, with features like graphical
outcomes recording, own data exportation and data bench-
marking analysis being offered through the platforms.
Conclusions
RWE provides a valuable contribution to the evidence
base for the use of MS therapies by supplementing RCT
data and providing information on long-term effective-
ness and tolerability of treatments in a real-world setting
across generalizable populations. It provides longitudinal
outcome information that can be directly used for phar-
macoeconomic evaluation and examination of treatment
patterns and sequencing outcomes. Robust study designs,
Table 2 Key multiple sclerosis (MS) registry studies in Europe,







Germany (MSDS3D Users) >5000
Greece (GMSS) 3500
Italy (iMed/web) ~20,000
Norway (Nasjonal kompetansetjeneste for




Spain (Catalonia; EpidEMcat) >5000
Sweden (SMSreg) 12,900
Switzerland (SMSR) 270
United Kingdom (MS Register) 8300
North America
Canada (London Ontario) 1099
Canada (British Columbia) 2837
USA (New York; NYSMSC) 9600a
USA (NARCOMS) 19,297
Global
MSBase (31 countries) 39,030
Patient numbers are derived from the original publications [30, 44] and may
have changed
aNumbers updated by NYSMSC, 6 May 2016
DMSC, Danish Multiple Sclerosis Center; DMSG, National Multiple Sclerosis
Society of Germany; EDMUS, European Database for Multiple Sclerosis;
EpidEMcat, Catalonia MS Registry; GMSS, Greek Multiple Sclerosis Society;
NARCOMS, North American Research Committee on Multiple Sclerosis;
NYSMSC, New York State Multiple Sclerosis Consortium; MSBase, Multiple
Sclerosis database; SDMSH, Croatian Multiple Sclerosis Society; SMSR, Scottish
Multiple Sclerosis Register; SMSreg, Swedish MS registry
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including appropriate data collection and analytical
methods as well as a unified minimum dataset, are crit-
ical for generating evidence that can be reasonably used
to influence treatment decisions and guidelines, and
satisfy the growing need of stakeholders to monitor
DMT performance post-approval.
RWE generation can be further expanded in MS, as
some important outcome measures are not routinely
collected in real-world databases. By collecting informa-
tion on additional outcome measures, such as MRI and
cognition, their importance in guiding treatment could
be examined. By continually expanding the data pool
through collaborations, the validity and utility of RWE
to physicians and regulatory bodies will be improved,
fostering greater and better physician/patient engagement.
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